干扰素联合阿德福韦酯治疗慢性乙型肝炎临床疗效分析

目的 探讨干扰素联合阿德福韦酯治疗慢性乙型肝炎的临床疗效.方法 选取90例慢性乙型肝炎患者为研究对象,随机分为干扰素组、阿德福韦酯组、干扰素联合阿德福韦酯组,各30例.观察三组患者治疗前后谷丙转氨酶（ALT）、谷草转氨酶（AST）变化,比较乙肝病毒基因（HBV-DNA）及乙肝病毒e抗原（HBeAg）阴转率.结果 治疗后,联合组ALT、AST下降幅度大于干扰素组和阿德福韦酯组（P＜0.01）;治疗12、24、48周时,联合组HBV-DNA阴转率高于干扰素组和阿德福韦酯组（P ＜0.05或P＜0.01）;治疗24、48周时,联合组HBeAg阴转率高于阿德福韦酯组（P＜0.01）.结论 干扰素联合阿德福韦酯治疗可抑制乙肝病毒,提高HBV-DNA、HBeAg阴转率,减轻肝细胞损伤.

Clinical efficacy of interferons combined with adefovir dipivoxil in treatment of chronic hepatitis B

Objective To study clinical efficacy of interferon combined with adefovir dipivoxil in treatment of chronic hepatitis B. Methods Ninety patients with chronic hepatitis B were divided into interferon group, adefovir dipivoxil group,interferon combined with adefovir dipivoxil group. ALT, AST, negative rate of HBV-DNA and HBeAg between three groups before and after the treatment were compared. Results ALT and AST of combination therapy group was lower than that of interferons group and adefovir dipivoxil group（ P 〈 0.01 ）. After 12 weeks,24 weeks and 48 weeks of treatment, HBV-DNA negative rate of the combination therapy group was higher than that of the interferons group and adefovir dipivoxil group（ P 〈0.05 or P 〈0.01 ）. 24 weeks and 48 weeks of treatment, HBeAg negative rate was higher than that of interferons group and adefovir dipivoxil group （ P 〈 0.01 ）. Conclusion Interferons combined with adefovir dipivoxil treatment can inhibit the hepatitis B virus,increase the negative rate of HBV-DNA and HbeAg and reduce liver cell damage.